Literature DB >> 20600575

Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs.

Iryna A Isakova1, Jason Dufour, Calvin Lanclos, Julie Bruhn, Donald G Phinney.   

Abstract

OBJECTIVE: Mesenchymal stem cells (MSCs) possess potent immunomodulatory activity, but whether they evade immune surveillance in an allogeneic transplant setting remains controversial. Herein we evaluated whether administration of major histocompatibility complex (MHC) class I-mismatched MSCs induce an immune response in rhesus macaques.
MATERIALS AND METHODS: MSCs from a male donor were injected intracranially at two different doses into eight immunocompetent female infant rhesus macaques. Blood cell counts and circulating levels of lymphocyte subpopulations were quantified prior to surgery and at 10, 30, and 90 to 180 days postsurgery by flow cytometry. Immunoreactivity of recipient peripheral blood mononuclear cells to donor MSCs was evaluated in vitro and alloantibody production in vivo was determined by enzyme-linked immunosorbent assay and flow cytometry.
RESULTS: MSC transplantation induced transient but significant increases in circulating white blood cells, lymphocytes, and neutrophils in most transplant recipients, but not sham-operated control animals. Flow cytometric analysis revealed a strong correlation between expansion of CD8(+), CD16(+), and CD8(+)/CD16(+) lymphocyte subpopulations in peripheral blood, the dose of administered MSCs, and degree of antigenic mismatch between donor and recipient. MSC-specific alloantibodies were also detected in several transplant recipients. However, peripheral blood mononuclear cells harvested from transplant recipients postsurgery exhibited no lytic activity against donor MSCs in vitro upon rechallenge.
CONCLUSIONS: MSCs induced an allograft response in rhesus macaques that involved principally CD8(+), CD16(+), and CD8(+)/CD16(+) lymphocyte subpopulations and was cell-dose- and haplotype-dependent. This study demonstrates that MSCs are weakly immunogenic in vivo when transplanted across MHC class I barriers.
Copyright © 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600575      PMCID: PMC2972653          DOI: 10.1016/j.exphem.2010.06.011

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  47 in total

Review 1.  Basic principles of immunological surveillance of the normal central nervous system.

Authors:  W F Hickey
Journal:  Glia       Date:  2001-11       Impact factor: 7.452

2.  Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates.

Authors:  Steven M Devine; Carrington Cobbs; Matt Jennings; Amelia Bartholomew; Ron Hoffman
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

Review 3.  Brain-immune connection: immuno-regulatory properties of CNS-resident cells.

Authors:  B Becher; A Prat; J P Antel
Journal:  Glia       Date:  2000-02-15       Impact factor: 7.452

Review 4.  The structural basis of T-cell allorecognition.

Authors:  A Whitelegg; L D Barber
Journal:  Tissue Antigens       Date:  2004-02

5.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

6.  Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.

Authors:  Massimo Di Nicola; Carmelo Carlo-Stella; Michele Magni; Marco Milanesi; Paolo D Longoni; Paola Matteucci; Salvatore Grisanti; Alessandro M Gianni
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

7.  Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.

Authors:  Alma J Nauta; Geert Westerhuis; Alwine B Kruisselbrink; Ellie G A Lurvink; Roel Willemze; Willem E Fibbe
Journal:  Blood       Date:  2006-05-11       Impact factor: 22.113

Review 8.  Of mice and not men: differences between mouse and human immunology.

Authors:  Javier Mestas; Christopher C W Hughes
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

9.  Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion.

Authors:  S M Devine; A M Bartholomew; N Mahmud; M Nelson; S Patil; W Hardy; C Sturgeon; T Hewett; T Chung; W Stock; D Sher; S Weissman; K Ferrer; J Mosca; R Deans; A Moseley; R Hoffman
Journal:  Exp Hematol       Date:  2001-02       Impact factor: 3.084

10.  Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals.

Authors:  Farida Djouad; Pascale Plence; Claire Bony; Philippe Tropel; Florence Apparailly; Jacques Sany; Danièle Noël; Christian Jorgensen
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

View more
  20 in total

Review 1.  Mesenchymal stromal cells in renal transplantation: opportunities and challenges.

Authors:  Federica Casiraghi; Norberto Perico; Monica Cortinovis; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-02-08       Impact factor: 28.314

Review 2.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

Review 3.  Mesenchymal stem cells: immune evasive, not immune privileged.

Authors:  James A Ankrum; Joon Faii Ong; Jeffrey M Karp
Journal:  Nat Biotechnol       Date:  2014-02-23       Impact factor: 54.908

Review 4.  Mesenchymal stem cell therapy of intestinal disease: are their effects systemic or localized?

Authors:  Nicholas A Manieri; Thaddeus S Stappenbeck
Journal:  Curr Opin Gastroenterol       Date:  2011-03       Impact factor: 3.287

5.  Extracellular purines promote the differentiation of human bone marrow-derived mesenchymal stem cells to the osteogenic and adipogenic lineages.

Authors:  Marilena Ciciarello; Roberta Zini; Lara Rossi; Valentina Salvestrini; Davide Ferrari; Rossella Manfredini; Roberto M Lemoli
Journal:  Stem Cells Dev       Date:  2012-12-21       Impact factor: 3.272

Review 6.  Mesenchymal stromal cells in transplantation rejection and tolerance.

Authors:  Karen English; Kathryn J Wood
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

Review 7.  Mesenchymal stem cell priming: fine-tuning adhesion and function.

Authors:  Dean P J Kavanagh; Joseph Robinson; Neena Kalia
Journal:  Stem Cell Rev Rep       Date:  2014-08       Impact factor: 5.739

8.  Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study.

Authors:  Larisa A Kuzmina; Natalia A Petinati; Elena N Parovichnikova; Lidia S Lubimova; Elena O Gribanova; Tatjana V Gaponova; Irina N Shipounova; Oxana A Zhironkina; Alexey E Bigildeev; Daria A Svinareva; Nina J Drize; Valery G Savchenko
Journal:  Stem Cells Int       Date:  2011-12-25       Impact factor: 5.443

9.  Modulation of human mesenchymal stem cell immunogenicity through forced expression of human cytomegalovirus us proteins.

Authors:  Melisa A Soland; Mariana G Bego; Evan Colletti; Christopher D Porada; Esmail D Zanjani; Stephen St Jeor; Graça Almeida-Porada
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

Review 10.  The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy.

Authors:  Jun Zhang; Xiaowen Huang; Haijun Wang; Xiaoyan Liu; Tao Zhang; Yunchuan Wang; Dahai Hu
Journal:  Stem Cell Res Ther       Date:  2015-12-01       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.